AltaGas is expected to achieve steady growth driven by its U.S. natural gas assets and strategic stake in the Mountain Valley Pipeline. The company forecasts an 8% increase in normalized EBITDA and a 6% rise in earnings per share for 2024. However, the stock currently trades at a high valuation of 17 to 25 times forward free cash flow, which limits near-term upside potential. While the dividend yield remains below 3% even after a recent increase, total returns will depend on the success of multi-billion-dollar growth investments and future free cash flow expansion. Common shares are rated as a hold, whereas Series G preferred shares offer an attractive fixed-income yield of 4.65%.
A regional nonprofit health plan reduced its Transparency in Coverage machine-readable file (MRF) production time from 45 days to less than 24 hours by integrating TALON's platform directly with its claims administration system. This eliminated a com...
ASUS has introduced two new Chromebooks in the US market: the budget-friendly CM15 laptop and the versatile CM32 Detachable 2-in-1 device. Both run on the MediaTek Kompanio 540 processor, offer up to 12 hours of battery life, and feature military-gra...
Slate Medicines, a biotech firm focused on migraine treatments, has appointed Mark W. Hahn to its Board of Directors. Hahn brings over 25 years of experience in life sciences, including leading companies through financial milestones and FDA approvals...
The global clinical trials market is projected to grow from $135.51 billion in 2026 to $176.32 billion by 2030, at a CAGR of 6.8%. Growth is fueled by advances in AI-enabled trial design, decentralized and hybrid trial platforms, and increasing deman...
The global hybrid robots market is projected to grow from $5.68 billion in 2026 to $10.03 billion by 2030, with a CAGR of 15.3%. Growth is fueled by advances in AI, autonomous operations, and smart manufacturing, alongside rising demand for robots in...
